LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Inicio・Lista de Acciones・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Cerrado

4.25 -0.7

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.24

Máximo

4.29

Métricas clave
By Trading Economics
Ingresos	-10M -7.7M
Ventas	-10M 529K
Margen de beneficio	-1,463.516
Empleados	44
EBITDA	-10M -7.7M

Dividendos
By Dow Jones
Próximas Ganancias	26 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	28M 908M
Apertura anterior	4.95
Cierre anterior	4.25

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

3.255 / 3.365 Soporte y Resistencia

Arbutus Biopharma Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 mar 2026, 19:08 UTC

Noticias de Eventos Importantes

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

13 mar 2026, 18:48 UTC

Ganancias

Principales Movimientos del Mercado

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

13 mar 2026, 17:10 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

13 mar 2026, 17:10 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions -2-

13 mar 2026, 16:47 UTC

Noticias de Eventos Importantes

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

14 mar 2026, 02:03 UTC

Ganancias

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14 mar 2026, 01:32 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14 mar 2026, 00:29 UTC

Adquisiciones, fusiones, absorciones

13D Filings -- Barrons.com

13 mar 2026, 22:27 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13 mar 2026, 22:13 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13 mar 2026, 22:04 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13 mar 2026, 22:00 UTC

Adquisiciones, fusiones, absorciones

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

13 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

13 mar 2026, 20:02 UTC

Charlas de Mercado

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13 mar 2026, 19:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13 mar 2026, 19:35 UTC

Noticias de Eventos Importantes

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

13 mar 2026, 19:00 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

13 mar 2026, 18:49 UTC

Noticias de Eventos Importantes

The Iran War Could Upend AI. Here's How. -- Barrons.com

13 mar 2026, 18:24 UTC

Noticias de Eventos Importantes

Impact of Middle East Conflict on TotalEnergies Activities

13 mar 2026, 18:00 UTC

Noticias de Eventos Importantes

Is War Good For the Economy? -- WSJ

13 mar 2026, 17:23 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

13 mar 2026, 16:46 UTC

Charlas de Mercado

Noticias de Eventos Importantes

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

13 mar 2026, 16:38 UTC

Noticias de Eventos Importantes

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

13 mar 2026, 16:34 UTC

Adquisiciones, fusiones, absorciones

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

13 mar 2026, 16:33 UTC

Adquisiciones, fusiones, absorciones

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

13 mar 2026, 16:32 UTC

Adquisiciones, fusiones, absorciones

EQT Completes Exit From Galderma

13 mar 2026, 16:20 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

13 mar 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

13 mar 2026, 16:15 UTC

Noticias de Eventos Importantes

Why Exxon and Energy Stocks Finally Started to Rise This Week as the Iran War Escalated -- Barrons.com

Comparación entre iguales

Cambio de precio

Arbutus Biopharma Corp Esperado

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Arbutus Biopharma Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

3.255 / 3.365Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.